Company to Participate in Two Q&A Sessions, Including a Joint Discussion with Zai Lab Company to Participate in Two Q&A Sessions, Including a Joint Discussion with Zai Lab

View original post here:
Turning Point Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days

Overallotment option on recent public offering partially exercised by underwriter

More here:
Outlook Therapeutics’ Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Through Planned BLA Submission

Milestone Marks Advance for Oral Mucosal Immunotherapy for Peanut Allergies Milestone Marks Advance for Oral Mucosal Immunotherapy for Peanut Allergies

The rest is here:
Intrommune Receives IND Clearance From U.S. Food and Drug Administration for INT301

Article reflects Company’s leadership and innovation in scalable, reproducible manufacture of adeno-associated virus (AAV)-based gene therapies

More here:
AGTC Executives Awarded First Place in the BioProcess International Reader’s Choice Awards, Cell & Gene Therapies Category

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc., (Alphageneron) signed an Exclusive License Agreement with Multimmune GmbH, of Munich, Germany, (Multimmune) on October 1st, 2020, for its clinical stage autologous Natural Killer (“NK”) cell therapy and companion diagnostic platform, for all fields worldwide.

Continue reading here:
Alphageneron Pharmaceuticals Signed Exclusive License Agreement With Multimmune GmbH For Natural Killer Cell Platform Therapy Worldwide

Read more:
Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2021

RALEIGH, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and full year 2020 results after the market closes on Thursday, February 25, 2021. The Company will also host a conference call on Friday, February 26, 2021 at 9:00 a.m. (ET) to discuss the results with members of the investment community.

See the rest here:
PRA Health Sciences to Report Fourth Quarter and Full Year 2020 Earnings

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented positive pre-clinical data from its Marzeptacog alfa (activated) – MarzAA, program, the Company’s subcutaneously (SQ) administered next-generation engineered activated coagulation Factor VII (FVIIa) for the treatment of episodic bleeding that is entering a Phase 3 registration trial. The data were presented by Tom Knudsen, D.V.M., Ph.D., vice president of translational research and Howard Levy, M.B.B.Ch., Ph.D., M.M.M., chief medical officer in poster sessions at the virtual 14th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD).

Link:
Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD...

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines administered by tablet, today announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its oral COVID-19 tablet vaccine candidate was generally well-tolerated, and immunogenic as measured by multiple markers of immune response to SARS-CoV-2 antigens.

Go here to see the original:
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

ROCKAWAY, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held virtually February 17-19, 2021.

Continue reading here:
electroCore to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Full enrollment triggered by observation of 3 objective responses in continued evaluation of the initial group of 8 patients Full enrollment triggered by observation of 3 objective responses in continued evaluation of the initial group of 8 patients

Read the original post:
PDS Biotech Announces Preliminary Efficacy Achievement in Phase 2 Combination Trial of PDS0101 Led by the National Cancer Institute

NEW YORK, NY, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,899,827 entitled “Antibodies Specific for Sulfation Sites of Sclerostin”.

Visit link:
Enzo Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin

TORONTO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that the Company has entered into a consulting agreement with the biomedical industry veteran Gregg Mayer, Founder & Principal of BioCore Strategies, LLC, Boston, Massachusetts, USA, and former executive of Abbott Diagnostics, Siemens and a number of early-stage biopharma and medical device companies, both public and privately held. Mr. Mayer will lead TELO’s efforts to develop and execute the Company’s industry partnership strategy with Biopharma and Diagnostics industries.

More:
Telo Genomics Retains Former Abbott & Siemens Veteran Gregg Mayer to Lead the Development of the Company’s Industry Partnership Strategy

SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today the initiation of clinical trials for ImmunoPass, the Company’s rapid point-of-care test that semi-quantitatively measures levels of neutralizing antibodies to COVID-19.

See more here:
AXIM® Biotechnologies Begins Clinical Trials on Its ImmunoPass Rapid Diagnostic Test With Vaccine Recipients

DAVIS, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, today released a letter to shareholders from Chief Executive Officer, Kevin Helash.

See more here:
Marrone Bio Innovations Issues Shareholder Letter

The access information for the investor conference call is as follows: Domestic US/Canada - 1-(866) 342-8588Direct Toll / International - 1-(203) 518-9865 Program Title: Generex Biotechnology Conference Call Conference ID – 61174

More:
Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Friday February 5, 2021 at 9:00 AM

Alliance for Regenerative Medicine Responds to EU Beating Cancer Plan

Go here to read the rest:
Alliance for Regenerative Medicine Responds to EU Beating Cancer Plan

San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced that members of its leadership team will present at several upcoming investment events in February, including the Small-Cap Growth Investor Conference, the Money Show February Virtual Expo, and the Benzinga Cannabis Capital Conference taking place virtually.

Read more here:
Skye Bioscience to Participate in Investment Conferences in February

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

See the rest here:
Medexus Announces Upsize to Previously Announced Bought Deal Public Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Originally posted here:
Red Light Holland Announces Increase in Bought Deal Equity Financing to $10 Million